BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055-1063. [PMID: 17596838 DOI: 10.1002/jmv.20935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am J Gastroenterol. 2009;104:2449-2457. [PMID: 19584831 DOI: 10.1038/ajg.2009.371] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
2 Boxall E, Sira J, Kaskar S, Workman J, Kelly D. Does genotype predict response to treatment in children infected with hepatitis B perinatally? J Med Virol. 2012;84:1535-1540. [PMID: 22930499 DOI: 10.1002/jmv.23308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int 2008;2:140-6. [PMID: 19669298 DOI: 10.1007/s12072-008-9046-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
4 Wen Z, Zhang H, Zhang M, Tan D, Li Q, Zhang H, Wu P, Deng L. Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. Hepat Mon. 2014;14:e10813. [PMID: 25237370 DOI: 10.5812/hepatmon.10813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Janssen HL, Buster EH. Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy. Journal of Hepatology 2009;51:224-6. [DOI: 10.1016/j.jhep.2009.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
7 Tsai KN, Chong CL, Chou YC, Huang CC, Wang YL, Wang SW, Chen ML, Chen CH, Chang C. Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral Transcription via TATA-Binding Protein and Induces Stress Granule Assembly. J Virol 2015;89:11406-19. [PMID: 26339052 DOI: 10.1128/JVI.00949-15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
8 Lok AS, Pan CQ, Han SB, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, Mchutchison JG, Ferrari C, Lee H, Gordon SC, Gane EJ. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology 2016;65:509-16. [DOI: 10.1016/j.jhep.2016.05.016] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 17.6] [Reference Citation Analysis]
9 Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49:S103-S111. [PMID: 19399806 DOI: 10.1002/hep.22956] [Cited by in Crossref: 151] [Cited by in F6Publishing: 132] [Article Influence: 12.6] [Reference Citation Analysis]
10 Song J, Zhou Y, Li S, Wang B, Zheng X, Wu J, Gibbert K, Dittmer U, Lu M, Yang D. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection. PLoS One 2014;9:e90977. [PMID: 24618716 DOI: 10.1371/journal.pone.0090977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
11 Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. International Journal of Infectious Diseases 2010;14:e941-53. [DOI: 10.1016/j.ijid.2010.03.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
12 Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-5. [DOI: 10.1007/s00535-009-0024-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
13 Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol. 2013;48:930-941. [PMID: 23065021 DOI: 10.1007/s00535-012-0688-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
14 Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2012;56:67-75. [PMID: 22307831 DOI: 10.1002/hep.25636] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
15 Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol. 2009;46:117-123. [PMID: 19651540 DOI: 10.1016/j.jcv.2009.07.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
16 Kurbegov AC, Sokol RJ. Hepatitis B therapy in children. Expert Review of Gastroenterology & Hepatology 2014;3:39-49. [DOI: 10.1586/17474124.3.1.39] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
17 Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010;52:441-449. [PMID: 20137824 DOI: 10.1016/j.jhep.2009.12.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
18 Huang CC, Kuo TM, Yeh CT, Hu CP, Chen YL, Tsai YL, Chen ML, Chou YC, Chang C. One single nucleotide difference alters the differential expression of spliced RNAs between HBV genotypes A and D. Virus Res. 2013;174:18-26. [PMID: 23501362 DOI: 10.1016/j.virusres.2013.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
19 Ito K, Yoneda M, Sakamoto K, Mizokami M. Virological and Clinical Characteristics of Hepatitis B Virus Genotype A. J Gastroenterol 2018;53:18-26. [PMID: 28687901 DOI: 10.1007/s00535-017-1367-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
20 Okanoue T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, Minami M, Imai Y, Yoshihara H, Mita E, Morikawa T, Nishiguchi S, Kawakami Y, Nomura H, Sakisaka S, Kurosaki M, Yatsuhashi H, Oketani M, Kohno H, Masumoto A, Ikeda K, Kumada H. Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatol Res 2016;46:992-1001. [PMID: 26670363 DOI: 10.1111/hepr.12638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012;26:939-49. [PMID: 22333748 DOI: 10.1097/QAD.0b013e328352224d] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
22 Ito K, Kim KH, Lok AS, Tong S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009;83:3507-17. [PMID: 19193799 DOI: 10.1128/JVI.02348-08] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
23 Erhardt A, Göbel T, Ludwig A, Lau GK, Marcellin P, van Bömmel F, Heinzel-Pleines U, Adams O, Häussinger D. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol. 2009;81:1716-1720. [PMID: 19697400 DOI: 10.1002/jmv.21588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
24 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]